|
May 13
|
Sector Update: Health Care Stocks Mixed Late Afternoon
|
|
May 13
|
Top Midday Gainers
|
|
May 13
|
Takeda shells out $100m to license AC Immune’s Phase II Alzheimer’s therapy
|
|
May 13
|
Takeda nabs option to license Alzheimer’s immunotherapies from AC Immune
|
|
May 13
|
Takeda Pharmaceutical, AC Immune Agree to Option and Licence Agreement, Including on Alzheimer's Treatment Candidate
|
|
May 13
|
AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update
|
|
May 13
|
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
|
|
Apr 11
|
We Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business Growth
|
|
Mar 15
|
Further weakness as AC Immune (NASDAQ:ACIU) drops 12% this week, taking three-year losses to 58%
|
|
Mar 14
|
AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update
|
|
Jan 22
|
AC Immune to Regain Global Rights to Crenezumab and Semorinemab
|
|
Dec 5
|
Is it a Good Idea to Invest in AC Immune (ACIU) Stock Now?
|
|
Dec 1
|
AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO
|
|
Nov 27
|
Are Medical Stocks Lagging Aquestive Therapeutics (AQST) This Year?
|
|
Nov 7
|
AC Immune to Present at the Jefferies 2023 London Healthcare Conference
|
|
Nov 3
|
AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
|
|
Nov 2
|
We're Not Very Worried About AC Immune's (NASDAQ:ACIU) Cash Burn Rate
|
|
Nov 2
|
AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer’s Disease as a Surrogate of Clinical Efficacy on November 9, 2023
|
|
Aug 4
|
AC Immune (ACIU) Reports Q2 Loss, Misses Revenue Estimates
|
|
Aug 4
|
AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update
|